Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04812366 · ClinicalTrials.gov registry record · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by University of British Columbia.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 315
- Enrollment target
- 9
- Study locations
NCT04812366: Recruiting Phase 2 study of Prostate Cancer, sponsored by University of British Columbia.
NCT04812366 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by University of British Columbia. The registered enrollment target is 315 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (48% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04812366, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by University of British Columbia.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 315 participants
- Enrollment target
- 9
- Study locations
Study Summary
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy specimens deemed unevaluable for genomic testing will remain on LHRHa plus APA for an additional 16 weeks. Participants with evaluable tissue will be assigned to one of the open-label sub-studies on the basis of genomic profiling results. Within each group, they will be randomized to a specific treatment arm either LHRHa plus APA alone or adding abiraterone acetate and prednisone, docetaxel or niraparib. The study will evaluate the response rate and outcomes after radical prostatectomy in each arm of the trial.
Primary Outcome
Pathological Minimal Residual Disease (pMRD): pathological minimal residual disease (pMRD) is defined as residual tumour 5mm or less.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Apalutamide 60mg Tab
- DRUG Abiraterone Acetate 250mg
- DRUG Prednisone 5mg Tab
- DRUG Niraparib 100mg Oral Capsule
Study Locations (9)
Ontario
- London Health Sciences Centre - London
- Ottawa Hospital Research Institute (OHRI) - Ottawa
- University Health Network - Toronto
California
- University of California Davis - Sacramento
Massachusetts
- Brigham & Women's Hospital - Boston
Michigan
- University of Michigan Health - Ann Arbor
Texas
- U.T. MD Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Center - Seattle
British Columbia
- Vancouver Prostate Centre - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2021-09-21 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 2 |
What NCT04812366 shows while recruiting
NCT04812366 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT04812366 lists 9 locations in 7 states (Ontario, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT04812366 about?
NCT04812366 is a clinical study titled "Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer". The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (A...
What is the current status of trial NCT04812366?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 315 participants. The study started on 2021-09-21. Estimated completion is 2026-04-01.
What conditions does trial NCT04812366 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT04812366?
The interventions under investigation include: Docetaxel (DRUG), Apalutamide 60mg Tab (DRUG), Abiraterone Acetate 250mg (DRUG), Prednisone 5mg Tab (DRUG), Niraparib 100mg Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT04812366?
This trial is sponsored by University of British Columbia, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04812366 being conducted?
This trial has 9 study locations across California, Massachusetts, Michigan, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04812366's enrollment target sits among peer trials
315 154th of 735 higher than 582 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- NCT06846320 · 315 participants · Phase 2
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI